Ultimovacs Past Earnings Performance
Past criteria checks 0/6
Ultimovacs's earnings have been declining at an average annual rate of -24.8%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
-24.8%
Earnings growth rate
-13.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -67.7% |
| Net Margin | n/a |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Ultimovacs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -189 | 61 | 0 |
| 30 Sep 23 | 0 | -204 | 59 | 0 |
| 30 Jun 23 | 0 | -186 | 57 | 0 |
| 31 Mar 23 | 0 | -165 | 59 | 0 |
| 31 Dec 22 | 0 | -168 | 57 | 0 |
| 30 Sep 22 | 0 | -148 | 58 | 0 |
| 30 Jun 22 | 0 | -153 | 54 | 0 |
| 31 Mar 22 | 0 | -168 | 51 | 0 |
| 31 Dec 21 | 0 | -165 | 47 | 0 |
| 30 Sep 21 | 0 | -138 | 47 | 0 |
| 30 Jun 21 | 0 | -126 | 46 | 0 |
| 31 Mar 21 | 0 | -124 | 49 | 0 |
| 31 Dec 20 | 0 | -121 | 46 | 0 |
| 30 Sep 20 | 0 | -121 | 39 | 0 |
| 30 Jun 20 | 0 | -108 | 39 | 0 |
| 31 Mar 20 | 0 | -77 | 19 | 0 |
| 31 Dec 19 | 0 | -61 | 17 | 0 |
| 30 Sep 19 | 0 | -48 | 15 | 0 |
| 30 Jun 19 | 0 | -48 | 16 | 0 |
| 31 Mar 19 | 0 | -59 | 25 | 0 |
| 31 Dec 18 | 0 | -55 | 24 | 0 |
| 30 Sep 18 | 0 | -50 | 23 | 0 |
| 30 Jun 18 | 0 | -42 | 18 | 0 |
| 31 Mar 18 | 0 | -35 | 17 | 0 |
| 31 Dec 17 | 0 | -33 | 17 | 0 |
| 31 Dec 16 | 0 | -29 | 13 | 0 |
Quality Earnings: 7UM is currently unprofitable.
Growing Profit Margin: 7UM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 7UM is unprofitable, and losses have increased over the past 5 years at a rate of 24.8% per year.
Accelerating Growth: Unable to compare 7UM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 7UM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 7UM has a negative Return on Equity (-67.73%), as it is currently unprofitable.